Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology
- Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden
- Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and potent anti-cancer immune responses
- Expanding R&D team to further develop AT-108 and broaden in vivo reprogramming pipeline
Lund, Sweden, 14 March 2024 – Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces a €30 million Series A financing. The funds will be used to support development of Asgard’s lead program AT-108 to IND-readiness by 2026, expand and reinforce its research and development team, and fuel new reprogramming modalities and delivery platforms to strengthen the pipeline. The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
